Investigation Launched into Possible Securities Fraud by Cerevel Therapeutics Holdings,

August 11, 2023

Categories: BiotechnologyTags: , , Views: 34

🌧️Trending News

Cerevel Therapeutics ($NASDAQ:CERE) Holdings, Inc. has recently been the subject of an investigation into a possible securities fraud. Pomerantz LLP is conducting an inquiry into the matter and is seeking more information. Cerevel Therapeutics Holdings, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for neurological and other related diseases. The company has a portfolio of drug candidates in various stages of development, ranging from preclinical to late clinical development. It has collaborations with multiple pharmaceutical companies, including Merck, Sanofi and Lundbeck.

The recent inquiry is investigating whether certain statements made by Cerevel Therapeutics Holdings, Inc. regarding its business, its financial condition and its prospects were false or misleading at the time they were made. If found to be true, this could constitute securities fraud. The inquiry is ongoing and investors are advised to monitor the situation closely.

Stock Price

Investors are now worried that the company may have misled investors about its finances and performance. As a result, investors are now closely monitoring the outcome of the investigation and any potential impacts on the stock price. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Cerevel Therapeutics. More…

    Total Revenues Net Income Net Margin
    0 -396.57
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Cerevel Therapeutics. More…

    Operations Investing Financing
    -340.13 -242.05 619.82
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Cerevel Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    894.35 543.85 2.75
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Cerevel Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -58.0% -28.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    As a part of our analysis, GoodWhale has taken a look at CEREVEL THERAPEUTICS’ wellbeing. After evaluating the company’s financial and business aspects, GoodWhale has placed it in the high risk category. Our in-depth analysis of CEREVEL THERAPEUTICS’ balance sheet, cashflow statement and financial journal has revealed three potential risk warnings. If you would like to review our findings, please register on We are confident that our analysis will help you take the best informed decisions when it comes to investing in CEREVEL THERAPEUTICS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s lead product candidates are CERE-120, an investigational dopamine receptor partial agonist, and CERE-210, an investigational N-methyl-D-aspartate receptor antagonist. The company is also developing CERE-133, an investigational adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Cerevel Therapeutics Holdings Inc’s main competitors are Galectin Therapeutics Inc, Immuron Ltd, Compugen Ltd. All three companies are engaged in the development of therapeutics for the treatment of central nervous system disorders.

    – Galectin Therapeutics Inc ($NASDAQ:GALT)

    Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapies to treat fibrosis and cancer. The company’s lead product candidate, belapectin, is in Phase 3 clinical development for the treatment of non-alcoholic steatohepatitis, or NASH. Galectin Therapeutics Inc. was founded by Harold A. Shlevin and Robert J. Lancefield in 2000 and is headquartered in Norcross, GA.

    – Immuron Ltd ($ASX:IMC)

    Immuron Ltd is an Australian-based biopharmaceutical company. The Company is engaged in the development of oral immunotherapy products for the treatment of autoimmune and infectious diseases. It operates in two segments: Research and Development, and Commercial. The Research and Development segment includes the Company’s activities related to the discovery, development and clinical evaluation of its products. The Commercial segment includes the marketing and sale of its products.

    – Compugen Ltd ($NASDAQ:CGEN)

    Compugen Ltd is a biopharmaceutical company focused on the development of therapeutic and diagnostic products based on predictive computational biology. The company has a market cap of $77.81M as of 2022 and a Return on Equity of -22.04%. The company’s products are based on its predictive computational biology platform, which it uses to identify therapeutic and diagnostic targets and develop novel therapeutics and diagnostics. Compugen’s products are designed to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases.


    Investors should exercise caution when considering investing in Cerevel Therapeutics Holdings, Inc. due to the recent announcement that Pomerantz LLP is investigating potential securities fraud. On the day of the announcement, the stock price of the company moved down significantly. It is important to pay attention to any updates on the investigation and consider the potential risks of investing in the company.

    Additionally, investors should review the company’s financials, corporate governance, and any other relevant information prior to investing. With any potential investment, it is important to thoroughly research the company and assess the risk-reward ratio.

    Recent Posts

    Leave a Comment